Silexion Therapeutics Corp
SLXN
$3.79
$0.061.61%
NASDAQ
| 12/31/2024 | 09/30/2024 | 03/31/2024 | 12/31/2023 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 12.48M | -4.82M | 289.00K | 1.48M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 23.24M | -8.04M | 1.25M | 7.63M | |
| Operating Income | -23.24M | 8.04M | -1.25M | -7.63M | |
| Income Before Tax | -31.27M | 11.86M | -1.42M | -8.48M | |
| Income Tax Expenses | 19.00K | -2.00K | 5.00K | 58.00K | |
| Earnings from Continuing Operations | -31.29M | 11.86M | -1.42M | -8.54M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | 152.00K | -9.00K | 50.00K | 380.00K | |
| Net Income | -31.14M | 11.85M | -1.37M | -8.16M | |
| EBIT | -23.24M | 8.04M | -1.25M | -7.63M | |
| EBITDA | -23.24M | 8.06M | -1.24M | -7.63M | |
| EPS Basic | -288.11 | 274.51 | -- | -- | |
| Normalized Basic EPS | -179.43 | 171.46 | -- | -- | |
| EPS Diluted | -288.11 | 274.51 | -- | -- | |
| Normalized Diluted EPS | -179.43 | 171.46 | -- | -- | |
| Average Basic Shares Outstanding | 108.10K | 43.20K | -- | -- | |
| Average Diluted Shares Outstanding | 108.10K | 43.20K | -- | -- | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |